Death during study period · adults with antisocial personality disorder
It is very uncertain whether psychosocial risk management ('Resettle' programme) changes adverse events: death during the study period Timing of assessment:… compared with treatment‐as‐usual (very low certainty).
1 finding from 1 review
Neonatal death (death within the first 28 days of life) · women of reproductive age ≥ 15 years.
Tetanus diphtheria toxoid immunisation of women of reproductive age may leads to lower neonatal mortality in the first 28 days of life compared with cholera toxoid (low certainty).
1 finding from 1 review
Neonatal mortality between day 4‐14 of life · women of reproductive age ≥ 15 years.
Tetanus diphtheria toxoid immunisation of women of reproductive age may leads to lower neonatal mortality between day 4‐14 of life compared with cholera toxoid (low certainty).
1 finding from 1 review
Death (fetal, neonatal, or later (up to 2 years' corrected age))** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death (fetal, neonatal, or later (up to 2 years' corrected age))** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate leads to lower cerebral palsy (up to 2 years' corrected age)** compared with placebo (outcomes (high certainty).
1 finding from 1 review
Death or cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate leads to lower death or cerebral palsy (up to 2 years' corrected age)** compared with placebo (outcomes (high certainty).
1 finding from 1 review
Major disability by 18 to 24 months corrected age (aligned definition) · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in major neurodevelopmental disability (up to 2 years' corrected age)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Death or major neurodevelopmental disability · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death or major neurodevelopmental disability (up to 2 years'… compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cumulative incidence of herpes zoster, 3.1 years · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to lower cumulative incidence of herpes zoster, 3.1 years compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccine Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events: 1 or more serious adverse events… compared with placebo (moderate certainty).
1 finding from 1 review
Cumulative incidence of herpes zoster at least 3.2 years · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to lower cumulative incidence of herpes zoster at least 3.2 years compared with placebo (moderate certainty).
1 finding from 1 review
Anaemia · population aged 2 years and above (Ballot 1989a (C) ‐ > 10 years, Chen 2005 (C) ‐ >3 years; Huo 2002 ‐ 11‐17 years, Longfils 2008‐ 6‐21…
It is very uncertain whether condiments/seasonings fortified with iron changes anaemia (defined as haemoglobin below WHO cut‐off for age and… compared with unfortified condiments/seasonings (very low certainty).
1 finding from 1 review
Anaemia · population aged 2 years and above (Andersson 2008 ‐ 5‐18 years, Asibey‐Berko 2007 ~ 3 years, Chen Ke 2008 ‐ 2‐6 years, Haas 2014 ‐ women…
Condiments/seasonings fortified with iron plus other micronutrients may leads to lower anaemia (defined as haemoglobin below WHO cut‐off for age and… compared with condiments/seasonings fortified with other micronutrients except iron (low certainty).
1 finding from 1 review
ADHD symptoms · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes ADHD symptoms: all parallel‐group trials and first‐period cross‐over… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Major neurological disability at 2 years of age (Defined as any of the following: legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy or developmental delay/intellectual impairment (developmental quoti... · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in major neurological disability at 2 years of age (Defined as any of… compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Breast cancer stage at the time of presentation: defined as the proportion of women with breast cancer diagnosed at early stage (stage 0, I, II) Time of outcome assessment: 3 years to 20 years Method of measurement: CBE · health workers
The intervention may leads to higher breast cancer stage at the time of presentation: defined as the… (low certainty).
1 finding from 1 review